造血干细胞移植
移植
医学
内科学
干细胞
微小残留病
CD19
免疫学
胃肠病学
抗原
白血病
肿瘤科
生物
遗传学
作者
Nan Yan,Na Wang,Gaoxiang Wang,Liang Huang,Chunrui Li,Di Wang,Jue Wang,Lifang Huang,Meng Fang,Jia Wei,Liting Chen,Xia Mao,Jianfeng Zhou,Yicheng Zhang,Yang Cao
出处
期刊:Cytotherapy
[Elsevier]
日期:2022-08-01
卷期号:24 (8): 841-849
被引量:14
标识
DOI:10.1016/j.jcyt.2022.01.011
摘要
B cell acute lymphocytic leukemia (B-ALL) patients who have relapsed after hematopoietic stem cell transplantation (HSCT) have a poor prognosis, and there is currently no standard approach available. Chimeric antigen receptor (CAR)-T cells induce high rates of initial response and long-term remission among patients with B-cell malignancies, especially B-ALL. Meanwhile, sequential infusion of CAR19/22 T cells has been proven to be effective at preventing tumor immune escape. In the present study, we retrospectively analyzed 23 B-ALL patients who relapsed after allogeneic (allo)-HSCT and underwent sequential infusion of CAR19/22 T cells, including nine donor-derived and 14 recipient-derived, in our center from July 2016 to July 2020, to evaluate the safety and efficacy of the cocktail of two single-specific CAR-T cells in B-ALL patients relapsed after transplantation. Except for one patient refusing evaluation, the remaining 22 patients achieved minimal residual disease (MRD)-negative complete remission within 30 days after CAR-T infusion. Most toxicities were slight and reversible. The estimated 12-month progression-free survival (PFS) rate was 59.2% (95% confidence interval [CI], 35.9% to 76.5%), and the estimated 12-month overall survival (OS) rate was 67.4% (95% CI, 43.2% to 83.1%). Only two patients had CD19-negative recurrence. In addition, early recurrence after transplantation, graft-versus-host disease (GVHD) and severe infection after CAR-T infusion were poor prognostic factors. Our results indicate that sequential infusion of CAR19/22 T cells is safe and effective for relapsed ALL patients after HSCT. This trial was registered at www.chictr.org.cn as #ChiCTR-OPN-16008526.
科研通智能强力驱动
Strongly Powered by AbleSci AI